Jonathan E. Lim - 03 Feb 2025 Form 4 Insider Report for Maze Therapeutics, Inc. (MAZE)

Role: Director
Signature: /s/ Courtney Phillips, as attorney-in-fact
Issuer symbol: MAZE
Transactions as of: 03 Feb 2025
Net transactions value: $0
Form type: 4
Filing time: 04 Feb 2025, 16:37:54 UTC
Previous filing: 30 Jan 2025
Next filing: 23 Jun 2025
SEC: View on sec.gov

Key filing fact

Jonathan E. Lim filed Form 4 for Maze Therapeutics, Inc. (MAZE) on 04 Feb 2025.

Key facts

This page summarizes Jonathan E. Lim's Form 4 filing for Maze Therapeutics, Inc. (MAZE).
7 reported transactions and 5 derivative rows are listed below.
Filing timestamp: 04 Feb 2025, 16:37.

Change

Previous filing in this sequence was filed on 30 Jan 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

See Original Filing

Transactions Table

MAZE transaction

Common Stock

Conversion of derivative security

Transaction value
Shares: +37,724
Change %
Price
Shares after: 37,724
Date: 03 Feb 2025
Ownership: City Hill, LLC
Footnotes: F1, F2

MAZE transaction

Common Stock

Conversion of derivative security

Transaction value
Shares: +270,232
Change %: +716%
Price
Shares after: 307,956
Date: 03 Feb 2025
Ownership: City Hill, LLC
Footnotes: F2, F3

MAZE holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 20,744
Date: 03 Feb 2025
Ownership: Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

MAZE transaction Derivative

Series A Preferred Stock

Conversion of derivative security

Transaction value
Shares: -363,703
Change %: -100%
Price
Shares after: 0
Date: 03 Feb 2025
Ownership: City Hill, LLC
Underlying class: Common Stock
Underlying amount: 37,724
Exercise price
Footnotes: F1, F2

MAZE transaction Derivative

Series B Preferred Stock

Conversion of derivative security

Transaction value
Shares: -2,231,381
Change %: -100%
Price
Shares after: 0
Date: 03 Feb 2025
Ownership: City Hill, LLC
Underlying class: Common Stock
Underlying amount: 270,232
Exercise price
Footnotes: F2, F3

MAZE transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares: +5,704
Change %
Price
Shares after: 5,704
Date: 09 Dec 2024
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 5,704
Exercise price: $10.42
Footnotes: F4, F5, F6

MAZE transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value
Shares: -5,704
Change %: -100%
Price
Shares after: 0
Date: 09 Dec 2024
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 5,704
Exercise price: $17.74
Footnotes: F4, F5, F6

MAZE transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +9,086
Change %
Price: $0.000000
Shares after: 9,086
Date: 09 Dec 2024
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 9,086
Exercise price: $10.42
Footnotes: F4, F7

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Pursuant to the Issuer's Restated Certificate of Incorporation, upon closing of the Issuer's initial public offering of its Common Stock, each share of Series A Convertible Preferred Stock automatically converted into shares of Common Stock at a ratio of 1-for-0.1037236801. The securities have no expiration date.
F2	These securities are directly held by City Hill, LLC, of which the reporting person is the managing partner.
F3	Pursuant to the Issuer's Restated Certificate of Incorporation, upon closing of the Issuer's initial public offering of its Common Stock, each share of Series B Convertible Preferred Stock automatically converted into shares of Common Stock at a ratio of 1-for- 0.1211056427. The securities have no expiration date.
F4	This transaction is an exempt transaction with the Issuer which occurred prior to the Issuer registering a class of equity securities under Section 12 of the Securities Exchange Act of 1934, as amended. It is reported herein as a transaction pursuant to Rule 16a-2(a). All numbers of shares and exercise prices have been adjusted to reflect a 1:9.641 reverse stock split of the Issuer's Common Stock effected on January 24, 2025.
F5	The option vested or vests as to 1/36th of the total award monthly, with the first tranche vesting on April 1, 2023, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date.
F6	This option, which was first granted on March 9, 2023, was canceled and exchanged for a new option having a lower exercise price in connection with an option repricing approved by the Issuer's Board of Directors on December 9, 2024. All terms of the option remained unchanged other than the exercise price.
F7	The option vested or vests as to 1/36th of the total award monthly, with the first tranche vesting on January 1, 2025, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date.